信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

INSIDE INFORMATION ANNOUNCEMENT
UPDATE ON THE COMPANY'S PRODUCT REVENUE IN THE FIRST QUARTER OF 2026

This announcement is made by Innovent Biologics, Inc. (the "**Company**" or "**Innovent**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

For the first quarter of 2026, the total product revenue amounted to over RMB3.8 billion, representing a robust year-over-year growth of over 50%. This strong momentum underscores the successful execution of our dual-engine strategy. Our oncology leadership became increasingly evident with the rapid commercial uptake of the five TKI (tyrosine kinase inhibitor) therapies newly included in the National Reimbursement Drug List (NRDL). Meanwhile, general biomedicine franchise has emerged as a powerful new growth driver, fueled by the strong performance of anchor assets, including mazdutide, SINTBILO® (tafolecimab injection), and SYCUME® (teprotumumab N01 injection).

The strong performance in the first quarter of 2026 reinforces our confidence in sustaining rapid revenue expansion, firmly establishing the Company as China's leading biopharma characterized by high certainty and growth. In addition, global innovation accelerates our value upside. We are advancing three high-potential assets into or towards global MRCT (multi-regional clinical trial) Phase 3 clinical trials: IBI363 (PD-1/IL-$2^{\alpha\text{-bias}}$), IBI343 (CLDN18.2 ADC) and IBI324 (VEGF/ANG2), backed by a deep, next-generation pipeline across oncology, cardiovascular and metabolism (CVM), autoimmune conditions, and ophthalmology. Looking ahead, the continuous progression of our domestic business and global pipeline development will steadily propel Innovent towards becoming a global premier biopharmaceutical company.

The financial information set out in this announcement was prepared based on internal management records of the Group which have not been audited or reviewed by external auditors, and as such, the data is for investors' information only. Such data may differ from figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company (including but not limited to those published on an annual or semi-annual basis), due to various uncertainties during the process of collection and collating of such data. This announcement does not constitute, nor should it be construed as, an offer or solicitation for the purchase or sale of any securities or financial instruments of the Group.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China,
April 30, 2026

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede and Ms. Qian Zhang as Executive Directors, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Dr. Shun Lu, Mr. Shuyun Chen and Dr. Stephen A. Sherwin as Independent Non-executive Directors.